FDA Boosts Novel Drug Aiming to Revolutionize Liver Transplants

IRVINE, CA – March 10, 2026 – The U.S. Food and Drug Administration (FDA) has granted a key designation to a promising new therapy that could fundamentally change the lives of liver transplant recipients, offering hope for a future with fewer debilitating side effects.

Eledon Pharmaceuticals announced today that its lead drug, tegoprubart, received Orphan Drug Designation for the prevention of organ rejection in liver transplantation. While a procedural step, the designation provides significant incentives for the development of treatments for rare conditions and underscores the potential of a drug that aims to solve a decades-old problem in transplant medicine: how to prevent rejection without harming the patient.

For thousands of patients who receive a life-saving liver transplant each year, the journey is far from over. They trade end-stage liver disease for a lifetime of powerful immunosuppressive drugs, a necessary bargain to keep their body from attacking the new organ. This new designation for tegoprubart highlights a pivotal shift towards a more targeted, potentially safer approach.

The Burden of Success: Life After Liver Transplant

For over two decades, the standard of care for preventing organ rejection has been dominated by a class of drugs called calcineurin inhibitors (CNIs), such as tacrolimus. These drugs are highly effective at suppressing the immune system, but they function as a sledgehammer, creating widespread collateral damage that patients endure for the rest of their lives.

The most feared complication is kidney damage. Many liver transplant recipients, despite having healthy kidneys before their operation, develop chronic kidney disease directly caused by the anti-rejection medications. A significant portion may eventually require dialysis or a kidney transplant.

Beyond the kidneys, the toxicity profile of CNIs is extensive. New-onset diabetes after transplant can affect up to 40% of patients, while 60-70% develop high blood pressure. Neurological side effects like tremors and headaches are common, and the broad immune suppression leaves patients vulnerable to opportunistic infections and an increased risk of cancer.

“For decades, we've been managing the trade-offs of our best available drugs,” commented one transplant immunologist not affiliated with the company. “A therapy that could effectively prevent rejection without causing long-term harm to the kidneys or metabolic system would be a paradigm shift. It’s the holy grail of transplant medicine.”

A New Approach: Targeting the Immune Response with Precision

Eledon’s tegoprubart is designed to be a more precise tool. As an anti-CD40L antibody, it targets a specific, well-validated pathway that is crucial for immune cell activation. By blocking the CD40 Ligand, tegoprubart aims to modulate the immune system, preventing the specific cells that cause rejection from activating without broadly suppressing the body's entire defense system.

“Clinical studies in kidney transplantation have demonstrated that tegoprubart has the potential to improve graft survival and function while reducing the side effects associated with calcineurin inhibitors, supporting its promise as a novel immunosuppressive therapy across multiple organ transplant settings,” said David-Alexandre C. Gros, MD, Chief Executive Officer of Eledon, in a statement. “Based on the encouraging preclinical evidence we have generated to date, we believe liver transplantation represents a significant incremental opportunity for tegoprubart.”

The company announced it anticipates an investigator-sponsored clinical trial for tegoprubart in liver transplantation to begin later this year, a critical step to prove its benefits in this specific patient population.

Building a Case: Promising Data from Other Transplants

The optimism surrounding tegoprubart is not based on theory alone. The drug has already generated compelling data in other settings, providing a strong foundation for its potential in liver transplantation.

In a recently completed Phase 2 study in kidney transplant recipients (the BESTOW trial), tegoprubart demonstrated comparable efficacy to tacrolimus in preventing rejection. More importantly, it showed a dramatically better safety profile. Kidney function, measured by eGFR, was better preserved in patients receiving tegoprubart. Furthermore, the incidence of CNI-associated side effects was substantially lower: new-onset diabetes occurred in just 1.6% of tegoprubart patients compared to 10.9% in the tacrolimus group, and tremors were seen in 1.6% versus 25%.

This ability to preserve kidney function is a crucial differentiator. As one expert noted, maintaining good kidney health in the first year after a transplant is critical for long-term survival and avoiding other major health issues.

Further evidence comes from an ongoing study in pancreatic islet cell transplantation for type 1 diabetes at the University of Chicago. Early results showed that all six evaluable patients treated with a tegoprubart-based regimen remained insulin-free, some for over a year, without the need for toxic CNIs. These patients have not experienced the kidney or neurological toxicity that typically accompanies such transplants.

This is the third Orphan Drug Designation for tegoprubart, which previously received the status for islet cell transplantation and for the treatment of amyotrophic lateral sclerosis (ALS), where it has also shown promise in reducing key inflammatory biomarkers associated with the neurodegenerative disease.

The Strategic Advantage of Orphan Drug Status

Securing Orphan Drug Designation is a significant strategic victory for a clinical-stage biotechnology company like Eledon. The designation is granted to drugs intended for rare diseases, defined as those affecting fewer than 200,000 people in the United States. While thousands receive liver transplants annually, the number falls within this definition.

The benefits are substantial and designed to de-risk and incentivize development. They include seven years of market exclusivity upon approval, protecting the drug from generic competition for that indication. Developers also receive a 25% tax credit on qualified U.S. clinical trial costs and are exempt from paying the substantial FDA user fees required for a new drug application, which currently exceed $4 million.

This package of incentives makes the development of drugs for smaller patient populations commercially viable, ensuring that companies can pursue innovations in areas of high unmet medical need. For Eledon, it provides a clearer and more supported regulatory pathway as it prepares to move tegoprubart into liver transplant trials.

As the transplant community looks toward the planned clinical trial, there is a palpable sense of anticipation. If tegoprubart can replicate its success from kidney and islet cell studies in the more complex setting of liver transplantation, it could usher in a new standard of care, finally allowing patients to reap the full benefits of their life-saving gift without the heavy toll of current therapies.